{"disease":{"id":"multiple-sclerosis-secondary-progressive","name":"multiple sclerosis secondary progressive"},"drugs":{"marketed":[{"drug_id":"mitoxantrone","indication_name":"Multiple Sclerosis - Secondary Progressive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06372145","title":"A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05204459","title":"MS-ResearchBiomarkerS","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT04688788","title":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04940065","title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen","phase":"","overall_status":"COMPLETED","enrollment_count":367,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06526000","title":"Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies","phase":"","overall_status":"COMPLETED","enrollment_count":326,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT07222618","title":"\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05961644","title":"Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Institute of Psychiatry and Neurology, Warsaw","has_results":false},{"nct_id":"NCT05663853","title":"An Observational Biomarker Study in Multiple Sclerosis (MS) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"LAPIX Therapeutics Inc.","has_results":false},{"nct_id":"NCT03283826","title":"Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":134,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false},{"nct_id":"NCT04260711","title":"Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).","phase":"NA","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT05893225","title":"Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT06395909","title":"A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT02988401","title":"Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT05327322","title":"Functional Outcomes From Diets in Multiple Sclerosis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT03653585","title":"Cortical Lesions in Patients With Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Danish Research Centre for Magnetic Resonance","has_results":false},{"nct_id":"NCT04705610","title":"Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography","phase":"NA","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Association de Recherche Bibliographique pour les Neurosciences","has_results":false},{"nct_id":"NCT07355387","title":"Home Based Functional Balance Intervention for Multiple Sclerosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT03783416","title":"SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05496881","title":"Exercise Effects in Multiple Sclerosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"University of Regina","has_results":false},{"nct_id":"NCT02305264","title":"Imaging of Intracerebral Inflammation in MS","phase":"NA","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05385731","title":"MUSCLE - Nordic Walking in MUltiple SCLErosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Leonardo A. Peyré-Tartaruga","has_results":false},{"nct_id":"NCT04918225","title":"Motor Asymmetry in Progressive Multiple Sclerosis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT03471338","title":"Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05013463","title":"Hydroxychloroquine and Indapamide in SPMS","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT06677710","title":"IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":34,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT04211740","title":"Phase II Clinical Trial of OCH-NCNP1","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"National Center of Neurology and Psychiatry, Japan","has_results":false},{"nct_id":"NCT07270120","title":"Senolytics for Secondary Progressive MS","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Ohio State University","has_results":false},{"nct_id":"NCT03493841","title":"Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Rebecca Spain","has_results":false},{"nct_id":"NCT07222956","title":"A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Moein Amin","has_results":false},{"nct_id":"NCT06436131","title":"The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Cyprus University of Technology","has_results":false},{"nct_id":"NCT06683612","title":"PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Contineum Therapeutics","has_results":false},{"nct_id":"NCT05357833","title":"Novel Imaging Markers in SPMS","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT02495766","title":"Autologous Mesenchymal Stromal Cells for Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Banc de Sang i Teixits","has_results":false},{"nct_id":"NCT06360861","title":"Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Tehran University of Medical Sciences","has_results":false}],"total":34},"guidelines":[],"source":"Drug Landscape verified database"}